IgG4-related sclerosing cholangitis: navigating diagnostic dilemmas and the challenge of relapse

Our plain-English summary of IgG4-related sclerosing cholangitis: navigating diagnostic dilemmas and the challenge of relapse, by X. Ren, X. Jin, L. Liu, et al (Frontiers in Medicine, 2026).

The study

• Authors: X. Ren, X. Jin, L. Liu, M. Zhang
• Journal: Frontiers in Medicine
• Published: 2026;13:1732637
• Type of article: Review
• Cited by: 2 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Background: Immunoglobulin G4-related sclerosing cholangitis (IgG4-SC), also termed IgG4-related cholangitis (IRC), is a challenging immune-mediated biliary disease, frequently mimicking malignancies such as cholangiocarcinoma (CCA) or other sclerosing cholangitides like primary sclerosing cholangitis (PSC). Accurate diagnosis is critical to avoid unnecessary surgical interventions.

Objective: This mini-review aims to synthesize the most current evidence on the pathogenesis, diagnostic pitfalls, and management strategies for IgG4-SC, with a focused discussion on overcoming diagnostic dilemmas and addressing the significant challenge of disease relapse.

Key Findings: The pathogenesis of IgG4-SC involves a complex interplay of genetic predisposition, environmental triggers (e.g., industrial vapors, dust, gases, fumes, and asbestos), and dysregulated adaptive immunity. A distinctive CD4+ T-cell response, dominated by T-helper 2 (Th2), follicular helper T (Tfh) cells, and regulatory T cells (Tregs), drives B-cell activation, oligoclonal expansion of IgG4+ plasmablasts, and progressive fibrosis. Notably, the discovery of IgG4/IgG1 autoantibodies against annexin A11 and laminin 511-E8 has provided insight into potential direct pathogenic mechanisms. Diagnosis relies on a multimodal approach integrating clinical presentation, characteristic imaging findings, elevated serum IgG4 levels (with levels >2× ULN being suggestive, and >4× ULN being highly specific), the IgG4/IgG1 ratio (>0.24), other organ involvement (notably type 1 autoimmune pancreatitis, AIP), supportive histopathology, and a rapid response to corticosteroid therapy. Despite high initial response rates to steroids, relapse occurs in 30%-50% of patients. Maintenance therapy with steroid-sparing immunomodulators (e.g., azathioprine, mycophenolate mofetil) or B-cell depleting agents such as rituximab is often required. The anti-CD19 monoclonal antibody inebilizumab has emerged as a potent new option for maintaining remission.

Conclusion: Maintaining a high index of clinical suspicion for IgG4-SC is essential in patients with obstructive jaundice and biliary strictures. Future efforts should focus on validating specific biomarkers (e.g., circulating plasmablasts, autoantibody profiles) and developing evidence-based protocols for long-term management to prevent fibrotic complications and reduce the relapse rate.

Copyright © 2026 Ren, Jin, Liu and Zhang.

In plain English

This mini-review summarized published evidence on IgG4-related sclerosing cholangitis (IgG4-SC), an immune-mediated bile duct disease that can mimic bile duct cancer (cholangiocarcinoma) or primary sclerosing cholangitis. The authors did not study any patients and did not describe how they chose the literature. Asbestos was mentioned twice, in the abstract and in a section on environmental triggers. Citing earlier studies, the authors wrote that long-term occupational exposure to industrial vapors, dust, gases, fumes and asbestos has been established as a significant environmental risk factor, which may contribute to the disease's male predominance. Drawing on cited work, the review reported that serum IgG4 is raised in approximately 80% of patients. It can also be modestly raised in 10%–15% of patients with primary sclerosing cholangitis or cholangiocarcinoma, so an elevated level alone is not diagnostic. Corticosteroids were described as first-line treatment, with relapse in 30%–50% of patients. Maintenance options included azathioprine, mycophenolate mofetil, rituximab and inebilizumab. The authors concluded that a high index of suspicion for IgG4-SC is essential in patients with obstructive jaundice and bile duct strictures, and that better biomarkers are needed.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Mini-review (narrative review of published evidence and guidelines); no search or selection methods described
• Who was studied: No study population. The authors reviewed published literature, international guidelines and clinical trials on IgG4-related sclerosing cholangitis.
• Exposure: Not studied by this review. Asbestos is mentioned twice: once in the abstract's list of environmental triggers, and once in section 2.1. In that section the authors cite other studies reporting long-term occupational exposure to industrial vapors, dust, gases, fumes (VDGF) and asbestos as an environmental risk factor. No fiber type is specified.
• Main results:
  • Citing other studies (references 9 and 12), the authors state that occupational exposure to vapors, dust, gases, fumes and asbestos may contribute to the strong male predominance in IgG4-SC.
  • Elevated serum IgG4 is reported in approximately 80% of patients with IgG4-SC (from cited literature).
  • Serum IgG4 can be modestly elevated in 10%–15% of patients with primary sclerosing cholangitis or cholangiocarcinoma. A level above four times the upper limit of normal is highly specific for IgG4-SC but has low sensitivity.
  • Standard induction treatment described is oral prednisolone 0.5 to 0.6 mg/kg/day for 2 to 4 weeks, tapered over 2 to 3 months.
  • Relapse occurs in 30%–50% of patients, often during steroid taper or after stopping steroids (from cited literature).
  • Reported relapse risk factors are proximal (hilar or intrahepatic) strictures, persistent bile duct wall thickening on imaging, and persistently elevated serum IgG4.
  • The authors report that inebilizumab, an anti-CD19 antibody, reduced relapse risk in a phase 3 randomized controlled trial (a separate cited study, reference 44).
  • According to the cited evidence, maintenance therapy should last a minimum of 3 years, with longer treatment considered for high-risk patients.
• The authors' conclusion: The authors concluded that a high index of clinical suspicion for IgG4-SC is essential in patients with obstructive jaundice and biliary strictures. They also concluded that the high relapse rate calls for better biomarkers to predict disease course and guide maintenance therapy.

Topics

Medical terms in this study, explained in our Lexicon: Fibrosis, Discovery, Histopathology, Monoclonal Antibody, Biomarker.

Related studies

• Desmoplastic malignant mesothelioma masquerading as sclerosing mediastinitis: a diagnostic dilemma — T.B. Crotty, T.V. Colby, et al. (1992)
• Environmental associations and histopathologic patterns of carcinoma of the lung: the challenge and dilemma in epidemiologic studies — J.C. Ives, P.A. Buffler, et al. (1983)
• Non-Asbestos-Related Malignant Peritoneal Mesothelioma: A Diagnostic Challenge in a Case of Unexplained Ascites — M.A.F. Dar, N. Nasir, et al. (2025)
• Well-differentiated papillary mesothelioma of the peritoneum: a diagnostic dilemma on fine-needle aspiration cytology — J.G. Nasit, G. Dhruva (2014)
• Pulmonary sclerosing hemangioma presenting with dense spindle stroma cells: a potential diagnostic pitfall — X.Y. Lin, Y. Wang, et al. (2012)
• Well differentiated papillary mesothelioma of abdomen- a rare case with diagnostic dilemma — A. Saha, P.K. Mandal, et al. (2018)

Browse more research in Frontiers in Medicine, or return to medical research.